Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow KINETA, INC./DE

Get SEC filing alerts via email and in your feed for KINETA, INC./DE

KA KANT

KINETA, INC./DE

About KINETA, INC./DE

Kineta is a biotechnology company focused on developing next-generation immunotherapies targeting innate immunity to treat cancer. Its pipeline includes monoclonal antibodies like KVA12123, a VISTA blocker, and anti-CD27 agonists, aimed at overcoming tumor immune resistance. The company targets solid tumors such as NSCLC, CRC, OC, RCC, and HNSCC, offering potential transformative treatments in the immuno-oncology market.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from KINETA, INC./DE

1
1
KINETA, INC./DE Kineta, Inc. Reports Reduced Losses and Strategic Initiatives Amid Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
KINETA, INC./DE Kineta, Inc. Reports $17.1 Million Net Loss and Explores Strategic Alternatives Amid Financial Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments

3
1
KINETA, INC./DE Kineta, Inc. Reports Significant Financial Challenges, Doubt About Its Ability to Continue as a Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments